First Flight Biosciences Enzyme Department has recently established a high throughput screening platform for histone deacetylase (HDAC) inhibitors. This new development brings HDB one step closer to a comprehensive solution provider in Epigenetic field. The cell based assay can measure HDAC activity from either living cells or nuclear extracts, whereas the biochemical screening assay is validated using mobility shift assay (MSA) format. The HTS-adapted screening platform allows quick identification of Histone deacetylase inhibitors (HDIs), a class of epigenetic therapeutic targets that have shown clinical success in various diseases, especially cancer therapy. The established HDIs screening platform, together with HDB’s other epigenetic capabilities in methyltransferase and demethylase, will provide our clients a rapid and reliable way to determine and validate the lead candidates against a wide spectrum of epigenetic targets, therefore promote epigenetic drug discovery.